Metabolic stability is a key factor to consider in the early stages of drug discovery. Even if a compound possesses promising pharmacological properties, it will never become a drug if it has poor metabolic stability. For instance, if a drug is rapidly metabolized in vivo, exposure levels may be insufficient, which could lead to the formation of toxic, inactive or active metabolites. Conversely, if a drug is metabolized slowly, it may remain in the body for a prolonged period, thereby triggering adverse reactions, toxicity, or drug interactions.
Metabolic stability testing is conducted to understand a compound's propensity for biotransformation in vivo. This allows the intrinsic clearance rate of a compound to be determined. A variety of in vitro test systems are employed when investigating drug metabolic stability, including liver microsomes, hepatocytes, S9 fractions, cytosol, recombinant enzymes and cell lines. The liver plays a key role in the biotransformation of foreign substances and is a primary target for drug toxicity. Searching for alternative liver models based on fish and other species is crucial for reducing the number of laboratory animals used in testing.
Creative Diagnostics has now launched the SpeXᵀᴹ Rainbow Trout Hepatocytes product range for drug metabolism research. These new products can help researchers accelerate drug development and are suitable for a variety of studies, including species-specific metabolism studies to predict metabolic differences between species, metabolic stability assessments to determine the metabolic clearance of compounds and support drug screening, and research into environmental pollutants and drug residues in aquatic systems.
Rainbow trout are a valuable species with rich nutritional value and a significant role in drug metabolism research. For many drugs, researchers have clearly identified the major cytochrome P450 (CYP) enzymes responsible for their metabolic transformation in humans. The liver of rainbow trout contains a complete enzyme system, including CYP450 (Phase I) and UGT (Phase II). Certain CYP450 isoenzymes in rainbow trout notably exhibit unique substrate specificity and metabolic kinetics compared to those in mammals, providing key insights into species-specific metabolism and interspecies differences.
Creative Diagnostics' new model provides accurate metabolic clearance data, making it a valuable asset in the early stages of drug screening. Furthermore, it plays a unique role in the study of environmental pollutants and drug residues in aquatic systems. Compared to traditional mammalian models, rainbow trout hepatocytes offer a fresh perspective on drug metabolism research, enriching studies in pharmacology and environmental toxicology.
For more information about SpeX™ Rainbow Trout Hepatocytes and the full range of ADME products and services, please visit https://qbd.creative-diagnostics.com/spex-rainbow-trout-hepatocytes.html.
About Creative Diagnostics
Creative Diagnostics is a global leader in the development and manufacturing of innovative tools and reagents for bioprocess impurity analysis. The company offers a comprehensive portfolio of solutions to support researchers in the quality control of biologics and provides biopharmaceutical quality, purity and safety assays, analytical methods and applications for the biotechnology and biopharmaceutical industries.
